Cargando…
Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO
BACKGROUND: Anti-GD2 therapy with dinutuximab is effective in improving the survival of high-risk neuroblastoma patients in remission and after relapse. However, allodynia is the major dose-limiting side effect, hindering its use for neuroblastoma patients at higher doses and for other GD2-expressin...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375533/ https://www.ncbi.nlm.nih.gov/pubmed/32697811 http://dx.doi.org/10.1371/journal.pone.0236115 |